key: cord-0690208-gtfrdjrh
authors: Antar, Annukka A R; Yu, Tong; Pisanic, Nora; Azamfirei, Razvan; Tornheim, Jeffrey A; Brown, Diane M; Kruczynski, Kate; Hardick, Justin P; Sewell, Thelio; Jang, Minyoung; Church, Taylor; Walch, Samantha N; Reuland, Carolyn; Bachu, Vismaya S; Littlefield, Kirsten; Park, Han-Sol; Ursin, Rebecca L; Ganesan, Abhinaya; Kusemiju, Oyinkansola; Barnaba, Brittany; Charles, Curtisha; Prizzi, Michelle; Johnstone, Jaylynn R; Payton, Christine; Dai, Weiwei; Fuchs, Joelle; Massaccesi, Guido; Armstrong, Derek T; Townsend, Jennifer L; Keller, Sara C; Demko, Zoe O; Hu, Chen; Wang, Mei-Cheng; Sauer, Lauren M; Mostafa, Heba H; Keruly, Jeanne C; Mehta, Shruti H; Klein, Sabra L; Cox, Andrea L; Pekosz, Andrew; Heaney, Christopher D; Thomas, David L; Blair, Paul W; Manabe, Yukari C
title: Delayed rise of oral fluid antibodies, elevated BMI, and absence of early fever correlate with longer time to SARS-CoV-2 RNA clearance in a longitudinally sampled cohort of COVID-19 outpatients
date: 2021-04-16
journal: Open Forum Infect Dis
DOI: 10.1093/ofid/ofab195
sha: 75e52b57f644cb146646af3e63a211112722f9ec
doc_id: 690208
cord_uid: gtfrdjrh

BACKGROUND: Sustained molecular detection of SARS-CoV-2 RNA in the upper respiratory tract (URT) in mild to moderate COVID-19 is common. We sought to identify host and immune determinants of prolonged SARS-CoV-2 RNA detection. METHODS: Ninety-five symptomatic outpatients self-collected mid-turbinate nasal, oropharyngeal (OP), and gingival crevicular fluid (oral fluid) samples at home and in a research clinic a median of 6 times over 1-3 months. Samples were tested for viral RNA, virus culture, and SARS-CoV-2 and other human coronavirus antibodies, and associations were estimated using Cox proportional hazards models. RESULTS: Viral RNA clearance, as measured by SARS-CoV-2 RT-PCR, in 507 URT samples occurred a median (IQR) 33.5 (17-63.5) days post-symptom onset. Sixteen nasal-OP samples collected 2-11 days post-symptom onset were virus culture positive out of 183 RT-PCR positive samples tested. All participants but one with positive virus culture were negative for concomitant oral fluid anti-SARS-CoV-2 antibodies. The mean time to first antibody detection in oral fluid was 8-13 days post-symptom onset. A longer time to first detection of oral fluid anti-SARS-CoV-2 S antibodies (aHR 0.96, 95% CI 0.92-0.99, p=0.020) and BMI ≥ 25kg/m(2) (aHR 0.37, 95% CI 0.18-0.78, p=0.009) were independently associated with a longer time to SARS-CoV-2 viral RNA clearance. Fever as one of first three COVID-19 symptoms correlated with shorter time to viral RNA clearance (aHR 2.06, 95% CI 1.02-4.18, p=0.044). CONCLUSIONS: We demonstrate that delayed rise of oral fluid SARS-CoV-2-specific antibodies, elevated BMI, and absence of early fever are independently associated with delayed URT viral RNA clearance.

Although severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections chiefly occur in the community, early virus and host response kinetics have been largely described in hospitalized inpatients. The logistics of recruiting and sampling potentially infectious individuals in the outpatient setting have sustained gaps in our knowledge of infectivity and pathogenesis in mild to moderate disease. In particular, it is not known whether antibody kinetics are tightly correlated on an individual level with viral RNA decay in mild to moderate COVID-19. Several case reports of prolonged shedding of infectious virus in immune compromised people with COVID-19 [1] [2] [3] [4] support the hypothesis that adaptive immunity is required for clearance of infectious virus. Two studies report that prolonged viral RNA shedding is correlated with lower peak SARS-CoV-2-specific IgG titers and lower numbers of B and T cells in blood [5, 6] . However, other studies report no difference in plasma SARS-CoV-2-specific antibody titers in patients testing positive or negative at late timepoints after symptom onset [7, 8] . Here we leveraged guided home sampling to longitudinally characterize viral and immune kinetics in a prospective cohort with mild to moderate COVID- 19 and identified associations with duration of viral RNA shedding from the upper respiratory tract that yield insights into COVID-19 pathogenesis.

Due to the timing of study enrollment and the contagious nature of COVID-19, obtaining a signed informed consent form for participants enrolled in this study was not feasible or safe for study staff. Instead, study staff obtained verbal consent using consent waiver with an alteration of informed consent. All participants provided verbal consent after documentation of understanding as they were isolating at home due to COVID-19, according to an approved consent script in either English or Spanish. A copy of the informed consent was sent to all participants. This protocol and verbal consent were approved by the Johns Hopkins 

The Johns Hopkins University (JHU) School of Medicine Institutional Review Board approved this study. Participants provided informed consent. The study prospectively enrolled a convenience sample of adults  30 years old within 48 hours of a positive SARS-CoV-2 reverse-transcriptase polymerase chain reaction (RT-PCR) test from an outpatient testing site of the Johns Hopkins Health System (JHHS) between April 21, 2020, and July 23, 2020 ( Figure 1A ) [9, 10] . The 95 symptomatic participants with known symptom onset date and who completed one or more RT-PCR tests after symptom onset were included here. Self-sampled mid-turbinate nasal swabs and oropharyngeal (OP) swabs were obtained with telephone guidance from study staff, and swabs were combined in 3mL viral transport medium and frozen. Mid-turbinate nasal-OP RT-PCR is equivalent to clinician-collected nasopharyngeal swabs [11] [12] [13] [14] [15] . Gingival crevicular fluid was obtained using the Oracol device (Malvern Medical Developments Ltd., Worcestershire, UK). Saliva was collected in the tube from June 1, 2020, onwards after validation of the spit saliva sample type [1] . The sampling schedule is shown in Figure 1B . Fifty-three of 95 participants presented to a research clinic visit at 1-4 months post-symptom onset for height, weight, vital signs, blood draw, nasopharyngeal swab, and oral fluid sampling. Symptom reports were collected by telephone at enrollment and on the same days as home and sample collection and are the primary source of symptom data. Symptom reports were cross-checked by reviewing clinical notes for symptom complaints from the electronic medical record.

RT-PCR testing of study samples was performed on the Abbott m2000 platform (Abbott Molecular, Des Plaines, Il) in 600 µl volumes [9] . Reported are cycle threshold (Ct) values from one of two primer/probe regions. Ct values < 31.5 was positive. 200 µl volumes of oral fluid were assayed by RT-PCR. The adequacy of self-collected nasal-OP and oral fluid A c c e p t e d M a n u s c r i p t 6 samples was confirmed via quantitative PCR for GAPDH human gene expression utilizing a TaqMan gene expression assay (ThermoFisher Scientific, Waltham, MA) (data not shown).

Positive nasal-OP samples by RT-PCR were tested for propagation of SARS-CoV-2 in cell culture [16] . Plasma SARS-CoV-2-specific antibody titers were quantified by indirect ELISA and neutralizing antibody titers were quantified by microneutralization assay [17, 18] .

Quantification of oral fluid SARS-CoV-2-specific IgG and other human coronavirus-specific IgG was obtained from a multiplex SARS-CoV-2 immunoassay based on Luminex technology [19, 20] . The oral fluid SARS-CoV-2-specific IgG readout of this assay is highly correlated with plasma SARS-CoV-2 neutralizing antibodies and plasma S-RBD-specific IgG by ELISA [19, 20] .

Kaplan-Meier plots and log-rank were generated using the 'survival' R package [21] .

Associations between covariates and clearance of upper respiratory tract SARS-CoV-2 viral RNA was determined via Cox proportional hazards models [21] after multiple imputation and model selection by least absolute shrinkage and selection operator (LASSO [22] . Model selection was performed using LASSO on each of the imputed datasets using the 'glmnet' R package [23] .

Nine variables were included in the model, which used the pooled imputed dataset . To determine whether the time from symptom onset to first detection of oral fluid SARS-CoV-2specific IgG is associated with RT-PCR clearance, we performed model selection using 

Study design. Ninety-five non-hospitalized, symptomatic individuals with a positive nasopharyngeal SARS-CoV-2 RT-PCR test from an emergency room or an ambulatory testing center within the previous 48 hours were enrolled between April 21, 2020, and July 23, 2020 ( Figure 1A ). Study day 0 was a median of 4 days (range 2-11) from the collection of the most recent prior positive RT-PCR test and was a median of 9 days from symptom onset (range 2-80). Participants presented for a single research clinic visit a median of 45 days after study day 0 (range 27-88).

Clinical characteristics. The median age of the participants was 56 years, and 59% were women (Table 1) . A total of 39% identified as Black or African American, and 14% as Hispanic/LatinX. The median body mass index (BMI) of participants was 29.3 kg/m 2 , similar to that of US adults, 29.4 kg/m 2 [24] . Eight participants (8.4%) required hospitalization after enrollment in the study [10] . Table 4 ).

onset. Oral fluid SARS-CoV-2-specific IgG to multiple viral antigens was assessed ( Supplementary Figures 2-4) . Longitudinal kinetics of oral fluid anti-SARS-CoV-2 S IgG by day from symptom onset are shown in purple in Figure 3A . Supplementary Table 4 shows the means and 95% confidence intervals of number of days from symptom onset to rise above cutoff for each of the eight SARS-CoV-2 antigens (8-13 days depending on the antigen), similar to that previously described [19] .

Kinetics of SARS-CoV-2 viral RNA clearance in outpatients. The median time to clearance was 33.5 days (range 4.5-150, IQR 17-63.5; Figure 4A ), similar to hospitalized COVID-19 patients with a similar mean age [28] . Table 1) .

COPD/asthma, early fever, and diabetes are associated with faster viral RNA clearance.

COPD/asthma, diabetes, and fever reported as one of first three COVID-19 symptoms were each associated with faster viral RNA clearance ( Figure 5 ). In four of five sensitivity analyses using different methods to estimate clearance, fever as one of first three reported COVID-19 symptoms remained associated with viral RNA clearance, whereas the association of diabetes and COPD/asthma was significant in fewer such analyses (Supplementary Tables   5-9) .

time to viral RNA clearance. In a time-dependent covariate Cox model (Cox model 2) for viral RNA clearance, a longer time to first detection of oral fluid spike-specific IgG is associated with longer time to viral RNA clearance (aHR 0.96, 95% CI 0.92-0.99, p=0.020) ( Table 2, Supplementary Tables 8-9 ).

Plasma SARS-CoV-2-specific antibody titer in convalescence is not associated with time to viral RNA clearance. Titers of plasma anti-S-RBD IgG, anti-S IgG, or neutralizing antibody in convalescence (measured once at 1-4 months post-symptom onset and treated as a baseline variable) were not significantly associated with viral RNA clearance in either direction. Additionally, the presence or absence of viral RNA by RT-PCR in the nasopharynx at 1-4 months post-symptom onset was not associated with plasma antibody titer (data not shown).

In a racially-and ethnically-diverse cohort of 95 adult outpatients with symptomatic COVID-19, we report that a longer time to first detection of oral fluid SARS-CoV2-specific antibodies is independently associated with a longer time to viral RNA clearance. We find that the presence of SARS-CoV-2 antibodies in oral fluid may be a predictor of negative A c c e p t e d M a n u s c r i p t 11 virus culture from nasal samples, even in samples with low RT-PCR Ct values. We demonstrate that the mean time from symptom onset to first detection of oral fluid SARS-CoV-2 S-RBD-IgG is 9-11 days, and virus culture positive samples may be detected through day 11 post-symptom onset in adults with mild-to-moderate COVID-19, one day longer than the current recommended isolation period [29] .

The strengths of this cohort are its size, its prospective and intensive longitudinal sampling design beginning in the acute phase of illness, its long duration of follow-up, and its simultaneous testing of samples for SARS-CoV-2 RT-PCR, virus culture, and oral fluid antibodies. Two studies of mostly outpatients included more cultured specimens but were not longitudinal [30, 31] . Our findings extend to the outpatient domain those described in 129 patients with severe COVID-19 by van Kampen and colleagues [32] , who report mean time from symptom onset to last positive virus culture of 8 days (maximum 20) , and that virus cultures were more likely to be negative when plasma neutralizing antibodies were elevated [32] . Our results suggest that outpatients testing positive for SARS-CoV-2 who have detectable oral fluid SARS-CoV-2-specfic antibodies are not likely to be transmissible, but larger studies are needed for confirmation.

We demonstrate that elevated BMI is also independently associated with longer time to viral RNA clearance. This association is not likely explained by increased prevalence of comorbidities such as hypertension or diabetes. In fact, diabetes, along with early fever and COPD/asthma, is associated with faster time to viral RNA clearance. Numerous studies report strong associations of COVID-19 severity and older age with viral RNA shedding duration [17, 33, 34] . Neither severity nor age were significantly associated with duration of viral RNA shedding in our study, likely because the vast majority of our cohort participants were in the same severity category and age range (IQR 49-64). Importantly, we found no effect of race or ethnicity with time to viral RNA clearance after adjustment for other demographic and comorbidities. Obesity is associated with testing positive for SARS-CoV-2, with severity of COVID-19, and with COVID-19 mortality [35] [36] [37] [38] . Dysregulated immunity is observed in severe COVID-19, aging, and obesity, and it may be the unmeasured key A c c e p t e d M a n u s c r i p t 12 correlate of viral RNA shedding duration. Aging drastically increases the chronic state of inflammation present in obesity [39] , perhaps explaining why our study of middle-aged and older participants uncovered the strong association of elevated BMI and viral RNA shedding duration. The other risk factors that correlated with longer time to viral RNA clearance in our studyabsence of early fever and longer time to detection of oral fluid antibodiesare consistent with impaired early innate and adaptive immune responses. Silva et al. report that a delay in antibody production is linked to high salivary viral loads in hospitalized patients [40] . We hypothesize that the chronic inflammatory state of aging and obesity hinders early innate and adaptive immune responses to SARS-CoV-2, leading to higher viral loads which require higher antibody titers and more time to clear, while also presenting a cytokine milieu in which it is stochastically more likely for a patient to tip into the positive feedback loops of hyperinflammation that portend disease severity. Mechanistic studies are needed to determine how obesity prolongs viral RNA shedding.

Our study has limitations, including that it is under-sampled at the time of symptom onset and at > 1 month from symptom onset. We address this by including clinician-ordered samples outside of the study, but the time to viral RNA clearance may be less precisely described in participants whose study samples at 1-3 months remained positive than others.

Our analytical approaches -Kaplan-Meier estimate, log-rank test, and Cox regression analyseswere designed to properly handle and correct bias caused by censored data. We minimize bias in estimated clearance by defining clearance as mid-point between last positive and subsequent negative test. Several sensitivity analyses using different clearance definitions demonstrate that our conclusions are supported by the evidence. There was a non-significant trend towards immunocompromised host status being associated with viral RNA shedding duration, which may appear to contrast with reports of prolonged viral carriage in immunocompromised people [1] [2] [3] [4] . This likely occurred because we grouped all immunocompromised people together, whereas there is probably a specific immunocompromised phenotype that leads to prolonged viral RNA detection. The associations of diabetes and COPD/asthma with faster time to viral RNA clearance were not A c c e p t e d M a n u s c r i p t 13 found to be independent of other covariates in all sensitivity analyses (diabetes) or our second Cox model (COPD/asthma), and conflict with one report of asthma being associated with longer viral RNA shedding [41] . Larger studies are needed to determine whether diabetes, COPD, or asthma are associated with time to viral RNA clearance. Finally, our study excluded people with asymptomatic SARS-Cov-2 infection, and so it is not yet clear whether these results are generalizable to asymptomatic infection.

In sum, we report viral and immune kinetics in an intensively characterized cohort of 95 adult outpatients with mild to moderate COVID-19. We demonstrate that elevated BMI, longer time to detection of oral SARS-CoV-2 IgG, and the absence of early fever are independently associated with longer time to viral RNA clearance, suggesting that functional early innate and adaptive immunity is critical for timely viral RNA clearance. M a n u s c r i p t Table 2 ) -were chosen for inclusion in the Cox proportional hazards model, which was performed using the pooled imputed

Saliva or Nasopharyngeal Swab Specimens for Detection of SARS-CoV-2

Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 Replication in an Immunocompromised Patient

Shedding of Viable SARS-CoV-2 after Immunosuppressive Therapy for Cancer

Prolonged viral shedding of SARS-CoV-2 in an immunocompromised patient

Dynamic changes in anti-SARS-CoV-2 antibodies during SARS-CoV-2 infection and recovery from COVID-19

Reduced numbers of T cells and B cells correlates with persistent SARS-CoV-2 presence in non-severe COVID-19 patients

Viral RNA level, serum antibody responses, and transmission risk in recovered COVID-19 patients with recurrent positive SARS-CoV-2 RNA test results: a population-based observational cohort study

Clinical, immunological and virological characterization of COVID-19 patients that test re-positive for SARS-CoV-2 by RT-PCR

Self-collected oral fluid saliva is insensitive compared to nasal-oropharyngeal swabs in the detection of SARS-CoV-2 in outpatients

The clinical course of COVID-19 in the outpatient setting: a prospective cohort study

Performance of Saliva, Oropharyngeal Swabs, and Nasal Swabs for SARS-CoV-2 Molecular Detection: A Systematic Review and Meta-analysis

A combined oropharyngeal/nares swab is a suitable alternative to nasopharyngeal swabs for the detection of SARS-CoV-2

Assessment of Sensitivity and Specificity of Patient-Collected Lower Nasal Specimens for Severe Acute Respiratory Syndrome Coronavirus 2Testing

Self-Collected Oral Fluid and Nasal Swab Specimens Demonstrate Comparable Sensitivity to Clinician-Collected Nasopharyngeal Swab Specimens for the Detection of SARS-CoV-2

Swabs Collected by Patients or Health Care Workers for SARS-CoV-2 Testing

Antigen-Based Testing but Not Real-Time Polymerase Chain Reaction Correlates With Severe Acute Respiratory Syndrome Coronavirus 2 Viral Culture

Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population

An immunosuppressed Syrian golden hamster model for SARS-CoV infection

COVID-19 Serology at Population Scale: SARS-CoV-2-Specific Antibody Responses in Saliva

Comparative performance of multiplex salivary and commercially available serologic assays to detect SARS-CoV-2 IgG and neutralization titers

Modeling survival data : extending the Cox model

Multivariate Imputation by Chained Equations in R

Regularization Paths for Generalized Linear Models via Coordinate Descent

Mean Body Weight, Height, Waist Circumference, and Body Mass Index Among Adults: United States

Repeat COVID-19 Molecular Testing: Correlation of SARS-CoV-2 Culture with Molecular Assays and Cycle Thresholds

Findings from investigation and analysis of re-positive cases

Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells

Impact of age on duration of viral RNA shedding in patients with COVID-19

COVID-19: Isolate if you are sick

Cell-based culture of SARS-CoV-2 informs infectivity and safe de-isolation assessments during COVID-19

Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19

Duration and key determinants of infectious virus shedding in hospitalized patients

Understanding viral shedding of severe acute respiratory coronavirus virus 2 (SARS-CoV-2): Review of current literature

SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis

The National COVID Cohort Collaborative: Clinical Characterization and Early Severity Prediction

Obesity in COVID-19: A Systematic Review and Metaanalysis

Body mass index (BMI) and outcomes of SARS-CoV-2 among US veterans

Body Mass Index and Prognosis of COVID-19 Infection

Aging, Obesity, and Inflammatory Age-Related Diseases

Saliva viral load is a dynamic unifying correlate of COVID-19 severity and mortality

Symptoms and Clinical Outcomes of Coronavirus Disease 2019 in the Outpatient Setting

BMI ≥ 25 kg/m 2 (referent: BMI < 25)

Race/ethnicity (referent: non-Hispanic White) African American or Black race